文献速递毛发、甲与色素性疾病

淋巴细胞性瘢痕性脱发的序贯小分子治疗:多中心前瞻性队列初步研究

Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study.
PubMed 文献 · J Am Acad Dermatol · 2026-03-09

本研究为多中心前瞻性队列初步研究,纳入33例组织病理学确诊的活动性淋巴细胞性瘢痕性脱发(LCA)成人患者,评估预设的三阶段序贯小分子治疗方案。31例完成方案,基线LPPAI从5.65±1.45显著降至III阶段0.75±0.27(改善率85.5%,P<.001),93.5%患者获显著改善,仅3例轻度不良事件。

要点

  • 三阶段序贯方案(托法替布+克立硼罗→阿普米司特+克立硼罗→克立硼罗单用)可显著降低LPPAI。
  • 31例完成者中93.5%达显著改善,仅3例轻度不良事件,耐受性良好。
  • 样本量小、无对照组、随访短,结论需更大规模对照研究验证。

核心结论

  • 在该患者队列中,三阶段序贯小分子方案耐受性良好,为活动性LCA提供了有前景的治疗选择。

研究设计与样本

  • 多中心前瞻性队列初步研究,在中国3家三级中心纳入33例组织病理学确诊的活动性LCA成人患者。
  • 方案分三阶段:I阶段口服托法替布+外用克立硼罗,II阶段口服阿普米司特+外用克立硼罗,III阶段单用外用克立硼罗。
  • 主要结局为纵向LPPAI及其改善率(ILPPAIS%)。

主要发现

  • 33例中31例完成方案。
  • 基线LPPAI为5.65±1.45,III阶段降至0.75±0.27(ILPPAIS% 85.5%,P<.001)。
  • 93.5%患者达显著改善,仅发生3例轻度不良事件。

临床怎么用

  • 对活动性LCA成人患者,可考虑三阶段序贯小分子方案作为治疗选择,但需结合个体情况并监测不良事件。

局限性

  • 样本量小。
  • 缺乏对照组。
  • 随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphocytic cicatricial alopecia (LCA) is a rare disorder causing irreversible hair follicle stem cell damage, with limited evidence supporting systemic treatments. OBJECTIVE: To assess the efficacy and safety of a predefined three-stage sequential small-molecule therapy for active LCA. METHODS: This multicenter prospective cohort pilot study enrolled adults with histopathologically confirmed active LCA at 3 Chinese tertiary centers. The regimen included oral Tofacitinib + topical Crisaborole (Stage I), oral Apremilast + topical Crisaborole (Stage II), and topical Crisaborole alone (Stage III). Primary outcomes were longitudinal Lichen Planopilaris Activity Index (LPPAI) and its improvement rate (ILPPAIS%). RESULTS: Of 33 patients, 31 completed the regimen. Baseline LPPAI (5.65 ± 1.45) decreased significantly to 0.75 ± 0.27 (ILPPAIS% 85.5%, P < .001) at Stage III; 93.5% achieved marked improvement with only 3 mild adverse events. LIMITATIONS: Small sample size, lack of control group, and short follow-up. CONCLUSION: In this patient cohort, three-stage sequential regimen was well tolerated and offers a promising treatment option for active LCA.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Li Y, Shao G, Tao Q, et al. Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study. J Am Acad Dermatol. 2026. PMID: 41812983. doi:10.1016/j.jaad.2026.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。